Boston Scientific announced that it has acquired EMcision, a company based in the United Kingdom and Canada.
The acquisition includes the Habib EndoHPB probe, a novel endoscopic bipolar radiofrequency device used for the treatment of pancreaticobiliary cancers.
“As we continue to search for ways to treat pancreaticobiliary cancers, we also seek to improve the quality of life for patients living with a cancer diagnosis today,” Art Butcher, senior vice president and president, endoscopy, at Boston Scientific said in a press release. “We are committed to exploring innovative options to help increase the chance of early diagnosis, improve treatment and advance the ability to remove cancers located in challenging areas of the gastrointestinal tract.”
The Habib EndoHPB probe is used to coagulate tissue ingrowth that blocks ducts that enable bile to drain out of the GI tract in patients with pancreaticobiliary cancers. The procedure helps prevent jaundice and improves patient quality of life, according to the press release.
The device has been cleared by the FDA and has received a CE mark from the European Commission.
Boston Scientific sought the acquisition to bolster its endoscopic portfolio with a device that helps address patient care for a cancer that leads to nearly 1 million deaths a year worldwide and for which there are limited treatment options, according to the press release.
Butcher is employed by Boston Scientific.